scholarly journals Defining the prognostic value of [15O]H2O positron emission tomography derived myocardial ischemic burden

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
P.A Van Diemen ◽  
J.T Wijmenga ◽  
R.S Driessen ◽  
M.J Bom ◽  
S.P Schumacher ◽  
...  

Abstract Background A myocardial ischemic burden (IB) of 10% is used to denote high-risk patients with coronary artery disease (CAD). This threshold has primarily been assessed by single-photon emission computed tomography. Differences in the pharmacokinetics of the utilized traces, higher resolution of positron emission tomography (PET), and lastly differences in assessment of IB might lead to a higher prognostic threshold for quantitative PET. Purpose To determine a [15O]H2O PET derived IB to identify low (annualized event rate (AER) <1.0%) and high (AER ≥3%) risk CAD patients. Methods 623 patients who underwent [15O]H2O PET because of suspected CAD and in whom follow-up was obtained were included. The IB was defined as the percentage of myocardium with a hyperemic blood flow (hMBF) ≤2.3 ml/min/g and by a coronary flow reserve (CFR) of ≤2.5. The endpoint was a composite of death and non-fatal myocardial infarction (MI). Time-dependent ROC curves were constructed for the prediction of the endpoint within the first 5-years, based on these curves thresholds were selected for which specificity was maximized and sensitivity was at least 80%. Patients were classified as having a high IB if their respective IBs were above the prognostic thresholds and as having a low IB if not. Results During a median follow-up of 6.7 years, 34 (6%) patients died and 28 (4%) experienced a MI resulting in 62 (10%) endpoints. An IB of 24% and 28% for hMBF and CFR, respectively, was found to be the optimal threshold to define prognosis. Patients with a high hMBF or high CFR IB had worse outcome compared to patients with a low IB (log-rank p<0.001 for both), with AERs of 0.6% vs. 2.8%, and 0.6% vs. 2.4% (p<0.001 for both), respectively. Patients with a concordantly high hMBF and CFR derived IB had the worst outcome (AER: 3.1%), whereas patients with a concordantly low or discordant IB result had a similarly low event rate of 0.5% and 0.9% (p=0.953), respectively (log-rank p=0.445). A concordantly high hMBF and CFR IB was an independent predictor of adverse outcome beyond clinical characteristics (adjusted hazard ratio: 3.52, p<0.001). Conclusion An IB of 24% and 28% for hMBF and CFR was found to be the optimal prognostic threshold. Both measurements can be used to determine patients outcome. However combining hMBF and CFR IB results leads to a further refinement of risk-stratification allowing for the identification of low (concordant low or discordant IB result) and high (concordant high IB result) risk CAD patients. Funding Acknowledgement Type of funding source: None

Author(s):  
Srikara Viswanath Peelukhana ◽  
Kranthi K. Kolli ◽  
Hanan Kerr ◽  
Mohamed Effat ◽  
Imran Arif ◽  
...  

Non-invasive diagnosis of coronary artery disease (CAD) is achieved using rest and stress myocardial perfusion imaging (MPI) techniques. Currently, the MPI technique that is a standard of care is the Single Photon Emission Computed Tomography (SPECT). However, comparatively accurate and reliable MPI diagnostic test known as Positron Emission Tomography (PET) is also available and gaining increasing popularity. In this study, a comparison is made between the impairments and left ventricular (LV) ejection fraction (EF) reported by SPECT and PET. In addition, using PET data, flow defects were quantified using coronary flow reserve (CFR: ratio of flow at stress to the rest) in four coronary territories, left ventricle (LV), left circumflex (LCX), right coronary artery (RCA) and left anterior descending (LAD). Three patients with previous SPECT and suspected CAD were consented and further assessed with a PET cardiac N-13 ammonia scan according to the study protocol. The comparisons of the two imaging modalities showed discordance for patients 1 and 2 while they concurred for the patient 3. More importantly, quantification of the extent of defect showed an abnormal CFR value (< 2) of 1.67 (LCX) and 1.57 (RCA) for the patient 1 and 1.67 (LAD) and 1.75 (RCA) for patient 2. For the third patient, CFR value was abnormal at 0.85 for the RCA. Therefore, in contrast to SPECT, quantification of flow impairment using PET MPI in individual coronary territories will aid in better diagnosis of CAD.


Author(s):  
Nikant Sabharwal ◽  
Parthiban Arumugam ◽  
Andrew Kelion

As in single photon emission computed tomography (SPECT), positron emission tomography (PET) involves the injection of a radiopharmaceutical, the physiological properties of which determine its distribution within the patient. The labelling radionuclide then allows this distribution to be imaged. The value of cardiac PET as a routine clinical tool, particularly for perfusion imaging, was previously limited by the expense and scarcity of cameras and the short half-lives of the radionuclides with complex radiochemistry. The need for an on-site cyclotron to produce these radiopharmaceuticals made a clinical service non-viable. A number of recent developments, however, have led to renewed interest in cardiac PET. This chapter covers PET instrumentation, detail on the radiopharmaceuticals used in cardiac PET, and a number of sections on F-fluorodeoxyglucose (F-FDG) PET covering infection and inflammation imaging.


2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Han Feng ◽  
Xiaobo Wang ◽  
Jian Chen ◽  
Jing Cui ◽  
Tang Gao ◽  
...  

Glucose homeostasis plays a key role in numerous fundamental aspects of life, and its dysregulation is associated with many important diseases such as cancer. The atypical glucose metabolic phenomenon, known as the Warburg effect, has been recognized as a hallmark of cancer and serves as a promising target for tumor specific imaging. At present, 2-deoxy-2-[18F]fluoro-glucose (18F-FDG)-based positron emission tomography/computed tomography (PET/CT) represented the state-of-the-art radionuclide imaging technique for this purpose. The powerful impact of 18F-FDG has prompted intensive research efforts into other glucose-based radiopharmaceuticals for positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging. Currently, glucose and its analogues have been labeled with various radionuclides such as 99mTc, 111In, 18F, 68Ga, and 64Cu and have been successfully investigated for tumor metabolic imaging in many preclinical studies. Moreover, 99mTc-ECDG has advanced into its early clinical trials and brings a new era of tumor imaging beyond 18F-FDG. In this review, preclinical and early clinical development of glucose-based radiopharmaceuticals for tumor metabolic imaging will be summarized.


Sign in / Sign up

Export Citation Format

Share Document